^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + epacadostat (INCB024360) (IDO1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Excerpt:
Patients received escalating doses of oral epacadostat (25, 50, 100, or 300 mg) twice per day plus intravenous pembrolizumab 2 mg/kg or 200 mg every 3 weeks....Among the two responders with RCC, each had intermediate and favorable Memorial Sloan Kettering Cancer Center risk, and one was PD-L1 positive. Both responses were maintained for approximately 15 months.
DOI:
10.1200/JCO.2018.78.9602
Trial ID:
